Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jun 22, 2021 11:18am
113 Views
Post# 33427091

RE:Needs the hard data still

RE:Needs the hard data stillThe hard human data will definitely boost the valuation, having said that when a preclinical cancer company valued twice THTX( no human data) a phase1/2 NASH company valued at 60% in comparison to THTX's valuation then one has to wonder if the current valuation is fair. The fact is since start of the year they attended two chats one on a relatively unknown retail oriented platform and the other one the Chat with Concord hosted by ED Nash who has been all over the place with his PTs recently. The LSA webinar was great but they need to keep promoting, some $2M has been ascribed to marketing, it would be useful to issue a PR announcing next presentation followed by the webinar. The relatively low profile strategy in today's wild wild west market won't get us where we want to be. They have gone through the transition to be an R&D company too now but that transition hasn't been processed by the market, let's hope they get that re-engineering plan going soon. They can't just rely on LSA to do all the heavy lifting but the company itself should be far more proactive. Failing that they will be ascribed more valuation after potential success of their operations but that valuation won't be fair either. 
Wino115 wrote:

While the new news was all positive yesterday, we still do need the first glimpse of POC and that all's like the lab work when done in humans.  We are getting there.  


But the new news was interesting commercially.  Now we have small cell lung as a possible target and since the trial is for all solid tumors expressing Sortilin, it's immediately a new market, and a large one at that.   


Secondly the data on using it to prevent metastic lesions for any solid tumor cancer.  Showing you essentially stopped lesions from spreading with a pre and post treatment of TH1902 versus just docetaxol alone shows you may want to just use it for any late stage solid tumor on their list to limit the spread to other organs and bones.  Once again a very interesting commercial opportunity that would be huge.  


We just need that safety, POC and human data to overcome the doubt that they are digging out from still.  



<< Previous
Bullboard Posts
Next >>